Compare SY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | AVIR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 266.4M |
| IPO Year | 2019 | 2020 |
| Metric | SY | AVIR |
|---|---|---|
| Price | $2.63 | $3.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $5.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 552.0K | 399.2K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $57.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $2.46 |
| 52 Week High | $6.28 | $4.02 |
| Indicator | SY | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 54.53 |
| Support Level | $2.46 | $3.34 |
| Resistance Level | $3.00 | $3.63 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.55 | 56.91 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).